Igor Koralnik to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Igor Koralnik has written about Antibodies, Monoclonal, Humanized.
Connection Strength
3.194
-
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology. 2014 Aug 19; 83(8):727-32.
Score: 0.464
-
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol. 2014 Jun; 75(6):925-34.
Score: 0.460
-
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol. 2013 Nov; 72(11):1043-51.
Score: 0.441
-
Gone over to the dark side: Natalizumab-associated JC virus infection of neurons in cerebellar gray matter. Ann Neurol. 2013 Oct; 74(4):503-5.
Score: 0.439
-
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012 Nov 20; 79(21):2160; author reply 2160.
Score: 0.413
-
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012 May 01; 78(18):1390-3.
Score: 0.397
-
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol. 2021 06 01; 78(6):736-740.
Score: 0.187
-
Can Immune Checkpoint Inhibitors Keep JC Virus in Check? N Engl J Med. 2019 04 25; 380(17):1667-1668.
Score: 0.161
-
Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol. 2010 Jun; 9(6):565-6; author reply 566-7.
Score: 0.087
-
Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009 Sep 10; 361(11):1067-74.
Score: 0.083
-
Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med. 2005 Jul 28; 353(4):414-6.
Score: 0.062